<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344148</url>
  </required_header>
  <id_info>
    <org_study_id>2008ZX10001-008</org_study_id>
    <nct_id>NCT01344148</nct_id>
  </id_info>
  <brief_title>Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.</brief_title>
  <official_title>AIDS and Tuberculosis Co-infection Treatment Strategies Study of China.[ Eleven Fifth Key Research Grant From the Ministry of Science and Technology, the People's Republic of China]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the best time to begin anti-HIV(Acquired Immunodeficiency Syndrome) treatment in
      individuals who co-infected with HIV and tuberculosis (Tb). This prospective, randomized
      study is being conducted on HIV/Tb co-infected patients in China to evaluate and compare the
      efficacy of antiretroviral therapy after 2 weeks TB treatment versus deferred ART initiated 8
      weeks after initiation of TB treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-Tb Therapy:
      2HREZ-4HRifb(H:Isoniazid，R:Rifampicin，E:Ethambutol，Z：pyrazinamide，Rifb:Rifabutin) HAART: The
      first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV) and the second line is
      Stavudine(D4T)+3TC+EFV Study group one: after anti-TB therapy 2 weeks begin with High Active
      Antiretroviral Therapy(HAART); study group two: after anti-TB therapy 8 weeks begin with
      HAART. If begin with HAART and the H change with Rifb.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 years</time_frame>
    <description>In China TB is the main co-infected disease of AIDS patients. This study will give the evidence for make the HIV and TB Co-infected Patients therapy tactics of China. At first, the study will prove what is the best time for begin HAART after anti-TB therapy 2 weeks or 8 weeks. And anti-TB and HAART program will also be confirmed in this study. Overall this research will measure the HIV and TB co-infected patients clinical treatment safety and tolerability of China.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients long-term survival.</measure>
    <time_frame>5 years</time_frame>
    <description>The two groups will be follow up for more than five years and the long-term survival will be value.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Anti- TB therapy HAART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH RIF Rifb PZA EMB AZT 3TC D4T EFV</intervention_name>
    <description>The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.</description>
    <arm_group_label>Anti- TB therapy HAART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of AIDS co-infected with TB CD4 T cell count lower than 350/ul Must
             be able to swallow tablets and finish the follow-up Sign the information consent form
             Chinese

        Exclusion Criteria:

          -  Can not tolerance the therapy estimated by the doctor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Hongzhou, MD. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Public Health Clinical Center Affliated to Fudan University China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Hongzhou, MD. PhD</last_name>
    <phone>+86 021 57248758</phone>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Yunzhi, MD</last_name>
    <phone>+86 021 57248763</phone>
    <email>zhangyunzhi3@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Hongzhou, MD, PhD</last_name>
      <phone>+86 021 57248758</phone>
      <email>Luhongzhou@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhang Yunzhi, MD</last_name>
      <phone>+86 021 57248758</phone>
      <email>Zhangyunzhi3@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lu Hongzhou</name_title>
    <organization>Shanghai Public Health Clinical Center Affiliated Fudan University</organization>
  </responsible_party>
  <keyword>Anti- TB</keyword>
  <keyword>HAART</keyword>
  <keyword>choice of the right moment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

